Skip to main content
Study examines safety, efficacy of alirocumab in diabetes

Researchers found that most patients with and without diabetes achieved less than 70 mg/dL of low-density lipoprotein cholesterol after 24 weeks of being treated with alirocumab. The findings in Diabetes Therapy, based on an analysis of five placebo-controlled phase 3 studies involving 3,459 patients with and without diabetes, revealed that 68.3% of patients with diabetes reached less than 70 mg/dL of cholesterol after receiving 75 mg of alirocumab every 2 weeks, compared with 65.8% of those without diabetes, and 78% achieved that level after receiving 150 mg, compared with 77% of those without diabetes.

Full Story: